Radiofrequency ablation in China typically costs from $11,100. Prices depend on the specific organ being treated, the technology used, and the clinic's location. In the United States, patients pay around $40,000 for similar procedures. China offers savings of approximately 72%. Costs generally include the probe, imaging guidance, physician fees, and hospital stay.
Bookimed Expert Insight: Choosing a clinic in Guangzhou offers access to high-volume expertise at competitive rates. Fuda Cancer Hospital is a notable example, where they hold JCI accreditation. They specialize in treating late-stage cancers using minimally invasive methods like NanoKnife. Many Chinese oncology directors, like Dr. Liuying, actively contribute to national treatment consensus. This local expertise ensures world-class standards for international patients seeking complex tumor ablation.
| China | Turkey | Austria | |
| Radiofrequency ablation | from $11,100 | from $5,400 | ≈ $7,500 |
| Transurethral needle ablation (TUNA) | ≈ $3,200 | ≈ $1,800 | ≈ $3,400 |
| Radiofrequency ablation with 3D mapping | from $8,500 | from $10,400 | ≈ $9,500 |
| Radiofrequency ablation of the liver | from $7,000 | ≈ $3,500 | ≈ $7,500 |
| Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) | from $9,000 | from $15,800 | ≈ $9,500 |
Prof. Liao Zhengyin brings deep expertise to the hospital, having performed 40,000+ procedures over more than 30 years. He served as a Senior Visiting Scholar at Johns Hopkins Hospital and founded the West China MDT team. The clinic focuses on Stereotactic Body Radiotherapy (SBRT) for early-stage cases and concurrent chemoradiotherapy for advanced stages. Patients benefit from low-dose spiral CT screening and PET-CT staging. For those unsuitable for surgery, the facility offers alternatives like cryoablation and iodine-125 seed implantation.
Day 1
Day 2
Day 3
Day 4
Week 1-2
Week 3
Week 4
Please note that each patient"s recovery timeline might differ slightly based on individual health conditions and the specifics of the procedure.
Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.
He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.
He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. Chen Yong Gang is the Head of Ultrasound Medicine at Xiamen Humanity Hospital. He has independently completed over 10,000 minimally invasive procedures. Dr. Chen specializes in ultrasound-guided ablation for thyroid, parathyroid, and gynecological conditions. He is a lead expert of the Thyroid Ablation Team.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Written by Kateryna Zamkovska
When considering Radiofrequency ablation, it’s important to understand the different techniques and which is best suited for you. Here’s a concise comparison of popular options:
This non-invasive procedure uses focused ultrasound waves under MRI guidance to treat specific medical conditions without incisions.
Radiofrequency ablation with 3D mapping is a minimally invasive procedure using radio waves to target and treat arrhythmias with precision.
Radiofrequency ablation of the liver is a minimally invasive procedure that uses heat generated by radio waves to destroy cancer cells in the liver.